Document text
Principal Investigator: Dori R Germolec
Organization: NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES
Fiscal Year: 2024
Award: $144,446
Funding agency: National Institute of Environmental Health Sciences
Our current work focuses on investigating specific cellular functions that have been demonstrated to be relevant to respiratory viral infection, including (influenza and SARS-CoV-2), susceptibility and pathogenesis by evaluating inflammatory and innate and adaptive immune responses. We are using an in vitro human whole blood assay system that can examine the impact of environmental factors, such as polyaromatic compounds, on lymphocyte cytotoxicity as well as selected immune functions from the same cell cultures and using multiple donors. To provide direct relevance to respiratory viral infections, we have incorporated evaluation of immune responses to viral antigens. To investigate interindividual susceptibility factors, human donors with a prior history of respiratory viral disease have been screened using the in vitro assays for immune response and challenged with viral antigens to provide information on the potential interactions with age, gender, and ethnicity. We have screened 200 donors and are evaluating the correlation between the independent variables of demographics and Covid history with immune endpoints. A second analysis strategy will examine the correlation between blood antibody levels and immune cell population counts/cytotoxicity, cytokine/chemokine production, and NK function. We have also partnered with collaborators in the Program on Reproductive Health and the Environment at the University of California San Francisco to develop a systematic evidence map of environmental factors that may impact the immune response to SARS-CoV-2. The protocol has been published and the team is currently evaluating results. Two papers describing the results of the first phase of these studies will be submitted for publication in 2024.
Study 2. Programs of work under development focus on addressing the key challenges affecting the uptake of MPS models for SARS-CoV-2 research, as identified by the MPSCoRe working group membership. The MPSCoRe working group identified a variety of scientific challenges, including model complexity and incorporation of innate and adaptive immune responses, and practical challenges, such as the need for model standardization, interlaboratory characterization, and defined performance criteria, and access to appropriate biosafety-level facilities, funding streams, and repositories of human tissues and cell sources. The University of Pittsburgh has developed a MPS Database (MPSDb), which aggregates MPS data with linked preclinical and clinical databases for analysis in the context of human exposure. NICEATM provided support for the development of a COVID-19 portal within the MPSDb, which provides links to COVID-19 disease information from Government and literature sources. This includes links to disease statistics, strategic responses, funding information, COVID-19 literature hubs and other scientific literature sites pre-queried forCOVID-19. Most recently, NICEATM has supported the further development of the COVID-19 portal to include an iPSC repository with details about cell sourcing and protocols. NICEATM is also working with NIAID and providing input and guidance on the overall design and coordination for a validation study of a MPS to evaluate the potential efficacy of prospective COVID-19 therapeutics prior to their study in a clinical setting. NICEATM and NC3Rs co-host an annual Summer Webinar Series (virtual, once per month) for the MPSCoRe working group members. Each agenda featured talks from two working group members and/or other invited MPS stakeholders or COVID researchers. On May 31-June 1, 2023 NICEATM and the MPSCoRe WG held a virtual workshop on Advancing Research and Regulatory Acceptance of Microphysiological Systems for Infectious Disease Applications.
Study 3. Building an AOP network modeling COVID-19 pathogenesis relies on interdisciplinary collaborative effort, synergizing exchange between experts from different fields to translate complex biology into messages understandable across disciplines. Currently, more than 60 scientists coming from 40 organizations are participating in the CIAO project. NICEATM is co-leading an effort to develop and publish an AOP for Neuro-COVID. Moreover, NICEATM is co-leading a systematic review-driven approach to facilitate data identification and analysis within CIAO and more generally into the AOP framework.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Address><Adoption><Affect><Age><Animals><Anosmia><Antibodies><Assay><Awareness><Bioassay><Biologic Models><Biological><Biological Assay><Biological Models><Biology><Blood><Blood Reticuloendothelial System><COVID infected patient><COVID patient><COVID positive patient><COVID-19><COVID-19 infected patient><COVID-19 pathogenesis><COVID-19 patient><COVID-19 positive patient><COVID-19 predisposition><COVID-19 susceptibility><COVID-19 therapeutics><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID-19 vulnerability><COVID19 pathogenesis><COVID19 patient><COVID19 positive patient><COVID19 virus><CV-19><California><Cell Body><Cell Culture Techniques><Cell Function><Cell Physiology><Cell Process><Cell-Mediated Cytolysis><Cell-Mediated Lympholysis><Cells><Cellular Cytotoxicity><Cellular Function><Cellular Immune Function><Cellular Physiology><Cellular Process><Chemotactic Cytokines><Clinical><Clinical Data><CoV-2><CoV2><Communicable Diseases><Complex><Coronavirus Infectious Disease 2019><Coronavirus disease 2019 predisposition><Coronavirus disease 2019 susceptibility><Coronavirus disease 2019 vulnerability><Cytotoxic cell><Data><Data Base Management><Data Base Management Systems><Data Bases><Database Management Systems><Databases><Development><Discipline><Disease><Disease Progression><Disorder><Ecological impact><Educational workshop><Ensure><Environment><Environmental Exposure><Environmental Factor><Environmental Impact><Environmental Risk Factor><Ethnic Origin><Ethnicity><Evaluation><Event><Funding><Future><Gender><Government><Grippe><History><Homologous Chemotactic Cytokines><Human><Immune><Immune response><Immunes><Immunological response><In Vitro><Individual><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Inflammatory><Influenza><Informatics><Innate Immune Response><Intercrines><International><Investigators><K lymphocyte><Knowledge><Laboratories><Link><Literature><Lymphocyte Cytotoxicity><Lymphocytotoxicity><Lytotoxicity><MOF syndrome><Maps><Model System><Modeling><Modern Man><Multiple Organ Dysfunction Syndrome><Multiple Organ Failure><NIAID><NK Cells><National Institute of Allergy and Infectious Disease><Natural Killer Cells><Outcome><Paper><Pathogenesis><Pathway interactions><Performance><Phase><Population><Predisposed to COVID-19><Predisposed to SARS-CoV-2><Predisposed to Severe acute respiratory syndrome coronavirus 2><Predisposition><Preparedness><Production><Protocol><Protocols documentation><Public Health><Publications><Publishing><Readiness><Recording of previous events><Reproductive Health><Research><Research Personnel><Researchers><Respiratory distress><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 infected patient><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 predisposition><SARS-CoV-2 susceptibility><SARS-CoV-2 therapeutics><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV-2 vulnerability><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 therapeutics><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SIS cytokines><San Francisco><Scientific Publication><Scientist><Series><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 predisposition><Severe acute respiratory syndrome coronavirus 2 susceptibility><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome coronavirus 2 vulnerability><Severe acute respiratory syndrome related corona virus 2><Site><Source><Standardization><Stream><Subcellular Process><Susceptibility><System><T-Cells><T-Lymphocyte><Technology><Tissue Arrays><Tissue Chip><Tissue Microarray><Toxicology><Translating><Universities><Viral><Viral Antigens><Viral Diseases><Viral Respiratory Tract Infection><Virus><Virus Diseases><Whole Blood><Work><Workshop><Wuhan coronavirus><adaptive immune response><adverse consequence><adverse outcome><ages><anosphrasia><authority><biologic><cell culture><cell cultures><cell mediated cytotoxicity><chemoattractant cytokine><chemokine><clinical database><coronavirus disease 2019><coronavirus disease 2019 infected patient><coronavirus disease 2019 pathogenesis><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 therapeutics><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 pathogenesis><coronavirus disease-19 patient><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus patient><cytokine><cytotoxicity><data base><database management><database systems><demographics><depository><design><designing><developmental><environmental risk><epidemic concern><epidemic potential><epidemic risk><epidemic threat><exposed human population><hCoV19><histories><host response><human exposure><human tissue><iPS><iPSC><iPSCs><immune function><immune system response><immunoresponse><in vitro Assay><in vitro testing><in vivo><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent stem cell><loss of smell><member><microphysiologic model><microphysiologic platform><microphysiologic system><microphysiology model><microphysiology platform><microphysiology system><multiorgan failure><multiple organ system failure><nCoV2><network models><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><olfactory loss><pathway><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><pre-clinical><preclinical><predisposed to Coronavirus disease 2019><programs><prospective><relational database management systems><repository><respiratory><response><safety assessment><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><statistics><susceptible to COVID-19><susceptible to Coronavirus disease 2019><susceptible to SARS-CoV-2><susceptible to Severe acute respiratory syndrome coronavirus 2><systematic review><technology platform><technology system><therapeutics against COVID-19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><thymus derived lymphocyte><treat COVID-19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><uptake><validation studies><viral infection><viral respiratory infection><virtual><virus antigen><virus infection><virus-induced disease><vulnerable to COVID-19><vulnerable to Coronavirus disease 2019><vulnerable to SARS-CoV-2><vulnerable to Severe acute respiratory syndrome coronavirus 2><webinar><work group><working group>